Vertex Pharmaceuticals Incorporated (VRTX) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Vertex Pharmaceuticals financial statements at a glance

Vertex Pharmaceuticals reported revenue of $12.00 billion for fiscal year 2025 (ended December 31, 2025), up 8.9% from fiscal year 2024. Net income was $3.95 billion, a net margin of 32.9%, and diluted earnings per share were $15.32.

At the end of fiscal year 2025 it had total assets of $25.64 billion, total liabilities of $6.98 billion and shareholders' equity of $18.67 billion, with cash and short-term investments of $6.61 billion and total debt of $2.03 billion.

Its operations brought in $3.63 billion of cash; capital spending was $437.60 million, leaving free cash flow of $3.19 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

VRTX logo

Vertex Pharmaceuticals Incorporated

VRTXUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
12.00B
Prev Year: 11.02B
YoY: +8.9%
Operating Revenue
11.97B
Prev Year: 11.02B
YoY: +8.6%
Tax Effect of Unusual Items
-56.63M
Prev Year: -971.86M
YoY: +94.2%
Total Unusual Items
-381.10M
Prev Year: -4.63B
YoY: +91.8%
Total Unusual Items Excluding Goodwill
-381.10M
Prev Year: -4.63B
YoY: +91.8%
Total Expenses
7.45B
Prev Year: 6.63B
YoY: +12.4%
Total Operating Income as Reported
4.17B
Prev Year: -232.90M
YoY: +1891.9%
Diluted NI Available to Com Stockholders
3.95B
Prev Year: -535.60M
YoY: +838.1%
Special Income Charges
-381.10M
Prev Year: -4.63B
YoY: +91.8%
Impairment of Capital Assets
379.00M
Restructuring and Mergers Acquisition
2.10M
Prev Year: -500.0K
YoY: +520.0%
Cost of Revenue
1.65B
Prev Year: 1.53B
YoY: +7.9%
Gross Profit
10.35B
Prev Year: 9.49B
YoY: +9.1%
Operating Expense
5.80B
Prev Year: 5.09B
YoY: +13.8%
Selling General and Administrative
1.75B
Prev Year: 1.46B
YoY: +19.7%
Research and Development
4.04B
Prev Year: 3.63B
YoY: +11.4%
Operating Income
4.55B
Prev Year: 4.39B
YoY: +3.6%
Net Non Operating Interest Income Expense
477.60M
Prev Year: 567.50M
YoY: -15.8%
Non-operating Interest Income
490.90M
Prev Year: 598.10M
YoY: -17.9%
Non-operating Interest Expense
13.30M
Prev Year: 30.60M
YoY: -56.5%
Other Income Expense
-388.80M
Prev Year: -4.71B
YoY: +91.8%
Other Non-operating Income (expense)
-7.70M
Prev Year: -86.10M
YoY: +91.1%
Pre-tax Income
4.64B
Prev Year: 248.50M
YoY: +1768.5%
Provision for Income Taxes
690.00M
Prev Year: 784.10M
YoY: -12.0%
Net Income Common Stockholders
3.95B
Prev Year: -535.60M
YoY: +838.1%
Net Income
3.95B
Prev Year: -535.60M
YoY: +838.1%
Net Income Including Non-Controlling Interests
3.95B
Prev Year: -535.60M
YoY: +838.1%
Net Income from Continuing Operations
3.95B
Prev Year: -535.60M
YoY: +838.1%
Basic EPS
15.46
Prev Year: -2.08
YoY: +843.3%
Average Dilution Earnings
-
Diluted EPS
15.32
Prev Year: -2.08
YoY: +836.5%
Weighted Average Shares (basic)
255.70M
Prev Year: 257.90M
YoY: -0.9%
Weighted Average Shares (diluted)
258.00M
Prev Year: 257.90M
YoY: +0.0%
Net Income from Continuing and Discontinued Operation
3.95B
Prev Year: -535.60M
YoY: +838.1%
Normalized Income
4.28B
Prev Year: 3.12B
YoY: +37.1%
Interest Income
490.90M
Prev Year: 598.10M
YoY: -17.9%
Interest Expense
13.30M
Prev Year: 30.60M
YoY: -56.5%
Net Interest Income
477.60M
Prev Year: 567.50M
YoY: -15.8%
EBIT
4.66B
Prev Year: 279.10M
YoY: +1568.4%
EBITDA
4.87B
Prev Year: 486.30M
YoY: +900.7%
Reconciled Cost of Revenue
1.65B
Prev Year: 1.53B
YoY: +7.9%
Reconciled Depreciation
209.80M
Prev Year: 207.20M
YoY: +1.3%
Net Income from Continuing Operation Net Minority Interest
3.95B
Prev Year: -535.60M
YoY: +838.1%
Normalized EBITDA
5.25B
Prev Year: 5.11B
YoY: +2.6%
Tax Rate for Calcs
0.149
Prev Year: 0
Values in USD

Vertex Pharmaceuticals key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$12.0B$11.0B$9.9B$8.9B$7.6B
Gross profit$10.4B$9.5B$8.6B$7.9B$6.7B
Operating income$4.6B$4.4B$4.3B$4.4B$2.8B
Net income$4.0B-$535.6M$3.6B$3.3B$2.3B
Diluted EPS$15.32-$2.08$13.89$12.82$9.01
Total assets$25.6B$22.5B$22.7B$18.2B$13.4B
Total liabilities$7.0B$6.1B$5.1B$4.2B$3.3B
Shareholders' equity$18.7B$16.4B$17.6B$13.9B$10.1B
Cash and short-term investments$6.6B$6.1B$11.2B$10.8B$7.5B
Total debt$2.0B$1.7B$808.4M$899.7M$967.4M
Operating cash flow$3.6B-$492.6M$3.5B$4.1B$2.6B
Capital spending$437.6M$485.4M$258.4M$204.7M$235.0M
Free cash flow$3.2B-$978.0M$3.3B$3.9B$2.4B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Vertex Pharmaceuticals's revenue in fiscal year 2025?

$12.00 billion, up 8.9% from $11.02 billion in fiscal year 2024.

How much profit does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals reported net income of $3.95 billion for fiscal year 2025 (32.9% of revenue); operating income was $4.55 billion.

How much cash and debt does Vertex Pharmaceuticals have?

At the end of fiscal year 2025: cash and short-term investments of $6.61 billion and total debt of $2.03 billion.

What is Vertex Pharmaceuticals's free cash flow?

$3.19 billion in fiscal year 2025 (operating cash flow of $3.63 billion minus capital spending of $437.60 million).

MoreVertex Pharmaceuticals stock overviewVertex Pharmaceuticals executive teamVertex Pharmaceuticals shareholdersVertex Pharmaceuticals revenue by segment
RelatedPharmaceutical Preparation Manufacturing industryManufacturing sectorInnoviva (INVA)Upstream Bio (UPB)Savara (SVRA)Gyre Therapeutics (GYRE)4D Molecular Therapeutics (FDMT)Sionna Therapeutics (SION)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube